Meeting
2023 ASCO Annual Meeting
The relationship between the change with neoadjuvant chemotherapy in the tumor-infiltrating lymphocyte (TIL) expressions and pathological response in breast cancer patients.
Authors
Ahmet Bilici
Istanbul Medipol University, Medical Faculty, Department of Medical Oncology, Istanbul, Turkey
Ahmet Bilici , Sabin Goktas Aydin , Asli Cakir , Omer Fatih Olmez , Vedat Bugra Erol
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3114)
DOI
10.1200/JCO.2023.41.16_suppl.3114
Abstract #
3114
Poster Bd #
312
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Evidence that neoadjuvant anthracycline based combination chemotherapy (NACT) in breast cancer (BC) induces phenotypical changes which guides the optimal adjuvant therapy.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2016 ASCO Annual Meeting
Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).
First Author: Fabricio Eugenio Racca
Poster
2013 Breast Cancer Symposium
Biomarkers predictive for pathologic response to neoadjuvant docetaxel/cyclophosphamide chemotherapy in primary breast cancer.
First Author: Kazuhiro Shimada
Poster
2013 ASCO Annual Meeting
The prognostic and predictive impact of genomic grade index (GGI) versus central grade or molecular class in intermediate-risk breast cancer (BC): Results from the EC-Doc trial.
First Author: Oleg Gluz